戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 as serine proteinases, histamine 4-receptor, 5-lipoxygenase-activating protein, 15-lipoxygenase-1, pr
2 mic stroke: phosphodiesterase 4D (PDE4D) and 5-lipoxygenase activating protein (ALOX5AP).
3                                 Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) is an arachi
4 genase (ALOX5) and its partner, arachidonate 5-lipoxygenase-activating protein (ALOX5AP), are involve
5                                              5-Lipoxygenase-activating protein, an arachidonate trans
6  in its consensus N-terminal two-thirds with 5-lipoxygenase-activating protein and has a region (resi
7 ing positive antibody binding to 5-LO, FLAP (5-lipoxygenase activating protein), and leukotriene A4 h
8 o-localizes with cPLA2alpha, 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 sy
9 enase (LO) activity and was inhibited by the 5-lipoxygenase-activating protein antagonist MK 886 and
10 diaI infarction, including ALOX5AP (encoding 5-lipoxygenase-activating protein) associated with myoca
11 to compensatory changes of 5-lipoxygenase or 5-lipoxygenase activating protein but rather an apparent
12 ave previously reported that exposure to the 5-lipoxygenase activating protein-directed inhibitor MK8
13 mology of its amino acid sequence to that of 5-lipoxygenase activating protein (FLAP) but none to tha
14                     Although deletion of the 5-lipoxygenase activating protein (FLAP) did not influen
15 n of five AA metabolizing enzymes as well as 5-lipoxygenase activating protein (FLAP) in a panel of h
16                                              5-Lipoxygenase activating protein (FLAP) inhibitors atte
17  A drug discovery program in search of novel 5-lipoxygenase activating protein (FLAP) inhibitors focu
18                                              5-lipoxygenase activating protein (FLAP) is abundantly p
19 diovascular disease, and an inhibitor of the 5-lipoxygenase activating protein (FLAP) is in clinical
20                                              5-Lipoxygenase activating protein (FLAP) plays a critica
21 s showed hypoxia augmented the expression of 5-lipoxygenase activating protein (FLAP), a key enzyme i
22 e show that expression of 5-lipoxygenase and 5-lipoxygenase activating protein (FLAP), key catalytic
23                We examined expression of the 5-lipoxygenase activating protein (FLAP), which is criti
24 ists of multimers of LTC(4) synthase and the 5-lipoxygenase activating protein (FLAP).
25  derivative 11j has an IC(50) of 4.2 nM in a 5-lipoxygenase-activating protein (FLAP) binding assay,
26    Specific inhibitors of 5-lipoxygenase and 5-lipoxygenase-activating protein (FLAP) blocked airway
27  we report that DBA/1 mice made deficient in 5-lipoxygenase-activating protein (FLAP) by gene targeti
28                                Inhibitors of 5-lipoxygenase-activating protein (FLAP) have been found
29 ed the mRNA expression of 5-lipoxygenase and 5-lipoxygenase-activating protein (FLAP) in human pulmon
30 n of a novel series of oxadiazole-containing 5-lipoxygenase-activating protein (FLAP) inhibitors are
31 he organization of 5-lipoxygenase (5-LO) and 5-lipoxygenase-activating protein (FLAP) into higher ord
32 ipase A2 (cPLA2), 5-lipoxygenase (5-LO), and 5-lipoxygenase-activating protein (FLAP), but lacked LTC
33 y proteins, coactosin-like protein (CLP) and 5-lipoxygenase-activating protein (FLAP), can support 5L
34 ere it associates with its scaffold protein, 5-lipoxygenase-activating protein (FLAP), to form the co
35 al to those of the human genes for LTC4S and 5-lipoxygenase-activating protein (FLAP).
36 fraction and increased levels of lung tissue 5-lipoxygenase-activating protein (FLAP).
37  hydrophobic domain and carboxyl terminus of 5-lipoxygenase-activating protein for that of LTC4S.
38 4 (LTD4) receptor antagonist MK-571, and the 5-lipoxygenase activating protein inhibitor MK-886 all s
39 as performed using diethylcarbamazine or the 5-lipoxygenase activating-protein inhibitor MK-886.
40 ctions in this model were examined using the 5-lipoxygenase-activating protein inhibitor MK-886.
41                         GSK2190915, a potent 5-lipoxygenase-activating protein inhibitor, prevents th
42                                          The 5-lipoxygenase-activating-protein inhibitor, MK-886, was
43                     The potent and selective 5-lipoxygenase-activating protein leukotriene synthesis
44 reatment of neutrophils with an inhibitor of 5-lipoxygenase-activating protein (MK886) and thus synth
45 or cysLT synthesis by MK886, an inhibitor of 5-lipoxygenase-activating protein, reduced the response
46                                              5-Lipoxygenase-activating protein rescues activity of 5-
47                          Human LTC4S and the 5-lipoxygenase-activating protein share substantial amin
48 lammation (cyclooxygenase 2, 5-lipoxygenase, 5-lipoxygenase-activating protein, tumor necrosis factor
49 tive protein and mRNA for 5-lipoxygenase and 5-lipoxygenase activating protein were present in cells
50 triene pathway, CYSLTR1, 5-lipoxygenase, and 5-lipoxygenase activating protein, whereas GPBAR1 gene e
51 re centered on the integral membrane protein 5-Lipoxygenase-Activating Protein, which we identify as